



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q102803

Takahide OHISHI, et al.

Appln. No.: 10/511,549

Group Art Unit: 1657

Confirmation No.: 9316

Examiner: Clark D PETERSEN

Filed: October 18, 2004

For: SCREENING METHOD OF AGENTS FOR INCREASING INSULIN CONTENT

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R. § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of

08/17/2007 CNGUYEN2 00000129 194880 10511549  
01 FC:1006 180.00 DA

INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No.: 10/511,549


Attorney Docket No.: Q102803

Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore the USPTO is directed and authorized to charge for the fee of \$180.00 under 37 C.F.R. § 1.17(p).

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,


  
\_\_\_\_\_  
Susan J. Mack  
Registration No. 30,951

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
**23373**  
CUSTOMER NUMBER

Date: August 16, 2007

Substitute for Form 1449 A &amp; B/PTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	Q102803
-------	---	----	---	------------------------	---------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
	1	US Application No. 11/657,110			CHEN et al.
	2	US 2003/0017528	A1	01-23-2003	CHEN et al.
	3	US 6,468,756		10-22-2002	BONINI et al.
	4	US 2003/0139590	A1	07-24-2003	BONINI et al.
	5	US 7,108,991	A1	09-19-2006	CHEN et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		
	6	GB	953,899		ROLF LAPPE et al.	
	7	EP	0 608 511	A2	BARBARA ARENA et al.	
	8	WO	87/01257	A2	PAUL MUNDER	
	9	WO	00/44382		BEYER et al.	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
	10	Communication enclosing a Supplementary Partial European Search Report for EPO Application No. EP 01998193, mailed March 11, 2005 (7 pages).	
	11	ATTWOOD, "The Babel of Bioinformatics", Science, 2000, 290: 471-473	
	12	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science, 1990, 247: 1306-1310	
	13	BURGESS et al., "Possible Dissociation of the Heparin-banding and Mitogenic Activities of Heparin-binding (Acid Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue", J. Cell. Biol., 1990, 111: 2129-2138	
	14	KUNTZ, "Structure-Based Strategies for Drug Design and Discovery", Science, 1992, 257: 1078-1082	
	15	LAZAR et al., "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities", Mol. Cell. Biol., 1998, 8: 1247-1252	
	16	METZLER et al., "Solution Structure of Human CTLA-4 and delineation of a CD/80/CD86 Binding Site Conserved in CD28", Nature Structural Biol., 1997, 4: 527-531	
	17	HOLZ et al., "cAMP-dependent Mobilization of Intracellular $\text{Ca}^{2+}$ Stores by Activation of Ryanodine Receptors in Pancreatic $\beta$ -Cells", J. Biological Chemistry, 247(20): 14147-14156 (1999)	
	18	Supplementary Partial European Search Report for EPO Application No. EP 01998193, mailed January 3, 2005	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/511,549
				Confirmation Number	9316
				Filing Date	October 18, 2004
				First Named Inventor	Takahide OHISHI
				Art Unit	1657
				Examiner Name	Clark D. PETERSEN
Sheet		2	of	2	Attorney Docket Number
		Q102803			

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
	US				
	US				
	US				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
	19	MILLER et al., "Ligand binding to Proteins: The Binding Landscape Model", Protein Science, 1997, 6: 2166-2179	
	20	RUDINGER, "1. Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence", From Peptide Hormones (ed. J. A. Parsons, M.A., B.M., B.Ch.), University Park Press, Baltimore, June 1976, pp. 1-7.	
	21	SKOLNICK et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotech, 2000, 18(1): 34-39	
	22	MESSER W.S. "Vasopressin and Oxytocin" [online], April 3, 2000 [retrieved on 2006-12-19]. Retrieved from the Internet:<URL: <a href="http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm">http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm</a> >	
	23	Restriction/Election Requirement dated November 1, 2006 in U.S. Application Serial No. 10/975,367	
	24	Response to Restriction Requirement filed on November 30, 2006 in U.S. Application Serial No. 10/975,367	
	25	Non-Final Office Action dated February 7, 2007 in U.S. Application Serial No. 10/975,367	
	26	Amendment as filed May 7, 2007 in response to Non-Final Office Action dated 2/7/2007 in U.S. Application Serial No. 10/975,367	
	27	Declaration of Patent Interference No. 105,561 [US Application 10/278,437 v. US Patent 7,108,991 and US Application 11/657,110]	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.